BACK

Kylor Hua

Kylor Hua

Executive Director

New York Office  |  kylor.hua@torreya.com   |   212.257.5817

Kylor Hua, an Executive Director at Torreya, advises clients on strategic transactions in the US and Asia.

He joined Torreya in 2013, having previously worked as a summer analyst at the firm.

Kylor received a B.A., magna cum laude from the University of Rochester. He holds double majors in economics and business strategy, and brain and cognitive science, and a minor in Japanese. He is fluent in Mandarin and Japanese.

Selected Transactions

Chiasma
Sale to
Amryt
$260 million
August 2021
Santen
Acquisition of
Eyevance
$225 million
September 2020
Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
VistaPharm
Company sale to
Warburg Pincus
$100+ million
December 2015
OtiTopic
Acquired by
PMI
August 2021
Oncosec Medical
Co-advisor on direct public offering
None
$15 million
August 2020
Oncosec Medical
Strategic investment from
China Grand and SirTex
$30 million
February 2020
Luoxin
JV Partnership
in China with
Aurobindo
$50 million
December 2018
Sandoz
Sale of
Sevelamer ANDA to
TWI Pharmaceuticals
October 2018
Tris
Debt recapitalization and acquisition of NextWave Pharmaceuticals from
Pfizer
$125 million
September 2018
EA Pharma
License of AJT-240 in hemodialysis in China to
Tasly Pharmaceutical Group Co., Ltd.
Up to $24 million
June 2018
Mission Pharmacal
Sale of consumer
products to
MainPointe Pharmaceuticals
February 2018
Sandoz
Sale of
ANDA portfolio to
CASI Pharmaceuticals
January 2018
Zylera
Sale to
Cerecor
Up to $34 million
November 2017
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Alphora Research
Sale of company to
Eurofins Scientific
June 2017
Apollo Endosurgery
Merger with
Lpath
$251 million
December 2016
Conatus Pharmaceuticals
Collaboration agreement for Emricasan with
Novartis
$50 million upfront
December 2016
Sandoz
Sale of ANDA
portfolio to
Upsher-Smith
October 2016
Hikma Pharmaceuticals
Sale of abbreviated
new drug applications
Undisclosed
February 2016
H2-Pharma
Sale of assets to
ANI Pharmaceuticals
$10 million
February 2016
telegent
Acquisition of
Alveda Pharmaceuticals
CAD $47 million
October 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
Teva
Sale of abbreviated
new drug application
portfolio to
ANI Pharmaceuticals
$25 million +
profit share
July 2015
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
March 2015
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014
Concordia International Corp.
Acquisition of
Donnatal® from
Revive Pharmaceuticals
$328 million
May 2014